131 related articles for article (PubMed ID: 17516024)
1. Dimethylamino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs: synthesis and cytotoxicity studies.
Hickey T; Claffey J; Fitzpatrick E; Hogan M; Pampillón C; Tacke M
Invest New Drugs; 2007 Oct; 25(5):425-33. PubMed ID: 17516024
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and cytotoxicity studies of new dimethylamino-functionalised and aryl-substituted titanocene anti-cancer agents.
Pampillón C; Claffey J; Strohfeldt K; Tacke M
Eur J Med Chem; 2008 Jan; 43(1):122-8. PubMed ID: 17412456
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and cytotoxicity studies of new morpholino-functionalised and N-heteroaryl-substituted titanocene anticancer drugs.
Hogan M; Claffey J; Pampillón C; Tacke M
Med Chem; 2008 Mar; 4(2):91-9. PubMed ID: 18336326
[TBL] [Abstract][Full Text] [Related]
4. Novel achiral titanocene anti-cancer drugs synthesised from bis-N,N-dimethylamino fulvene and lithiated heterocyclic compounds.
Pampillón C; Claffey J; Hogan M; Tacke M
Biometals; 2008 Apr; 21(2):197-204. PubMed ID: 17665139
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and cytotoxicity studies of titanocene C analogues.
Hogan M; Claffey J; Fitzpatrick E; Hickey T; Pampillón C; Tacke M
Met Based Drugs; 2008; 2008():754358. PubMed ID: 18274663
[TBL] [Abstract][Full Text] [Related]
6. Heteroaryl substituted titanocenes as potential anti-cancer drugs.
Sweeney N; Gallagher WM; Müller-Bunz H; Pampillón C; Strohfeldt K; Tacke M
J Inorg Biochem; 2006 Sep; 100(9):1479-86. PubMed ID: 16764931
[TBL] [Abstract][Full Text] [Related]
7. Bioorganometallic fulvene-derived titanocene anti-cancer drugs.
Strohfeldt K; Tacke M
Chem Soc Rev; 2008 Jun; 37(6):1174-87. PubMed ID: 18497930
[TBL] [Abstract][Full Text] [Related]
8. Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay.
Weber H; Claffey J; Hogan M; Pampillón C; Tacke M
Toxicol In Vitro; 2008 Mar; 22(2):531-4. PubMed ID: 17981007
[TBL] [Abstract][Full Text] [Related]
9. Pseudo-halide derivatives of titanocene: synthesis and cytotoxicity studies.
Claffey J; Deally A; Gleeson B; Hogan M; Méndez LM; Müller-Bunz H; Patil S; Wallis D; Tacke M
Metallomics; 2009 Nov; 1(6):511-7. PubMed ID: 21305159
[TBL] [Abstract][Full Text] [Related]
10. Oxali-titanocene Y: a potent anticancer drug.
Claffey J; Hogan M; Müller-Bunz H; Pampillón C; Tacke M
ChemMedChem; 2008 May; 3(5):729-31. PubMed ID: 18186097
[No Abstract] [Full Text] [Related]
11. Synthesis and biological evaluation of achiral indole-substituted titanocene dichloride derivatives.
Deally A; Hackenberg F; Lally G; Tacke M
Int J Med Chem; 2012; 2012():905981. PubMed ID: 25954531
[TBL] [Abstract][Full Text] [Related]
12. Methoxy-phenyl substituted ansa-titanocenes as potential anti-cancer drugs derived from fulvenes and titanium dichloride.
Tacke M; Cuffe LP; Gallagher WM; Lou Y; Mendoza O; Müller-Bunz H; Rehmann FJ; Sweeney N
J Inorg Biochem; 2004 Dec; 98(12):1987-94. PubMed ID: 15541486
[TBL] [Abstract][Full Text] [Related]
13. In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.
Kelter G; Sweeney NJ; Strohfeldt K; Fiebig HH; Tacke M
Anticancer Drugs; 2005 Nov; 16(10):1091-8. PubMed ID: 16222151
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer applications of titanocene-functionalised nanostructured systems: an insight into cell death mechanisms.
Ceballos-Torres J; Virag P; Cenariu M; Prashar S; Fajardo M; Fischer-Fodor E; Gómez-Ruiz S
Chemistry; 2014 Aug; 20(34):10811-28. PubMed ID: 24715574
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic studies of substituted titanocene and ansa-titanocene anticancer drugs.
Gómez-Ruiz S; Kaluderović GN; Prashar S; Polo-Cerón D; Fajardo M; Zizak Z; Sabo TJ; Juranić ZD
J Inorg Biochem; 2008 Aug; 102(8):1558-70. PubMed ID: 18353439
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and cytotoxicity studies of steroid-functionalized titanocenes as potential anticancer drugs: sex steroids as potential vectors for titanocenes.
Gao LM; Vera JL; Matta J; Meléndez E
J Biol Inorg Chem; 2010 Aug; 15(6):851-9. PubMed ID: 20349254
[TBL] [Abstract][Full Text] [Related]
17. Titanocene difluorides with improved cytotoxic activity.
Eger S; Immel TA; Claffey J; Müller-Bunz H; Tacke M; Groth U; Huhn T
Inorg Chem; 2010 Feb; 49(4):1292-4. PubMed ID: 20055428
[TBL] [Abstract][Full Text] [Related]
18. New titanocene derivatives with high antiproliferative activity against breast cancer cells.
Saturnino C; Sirignano E; Botta A; Sinicropi MS; Caruso A; Pisano A; Lappano R; Maggiolini M; Longo P
Bioorg Med Chem Lett; 2014 Jan; 24(1):136-40. PubMed ID: 24332626
[TBL] [Abstract][Full Text] [Related]
19. A new generation of anticancer drugs: mesoporous materials modified with titanocene complexes.
Pérez-Quintanilla D; Gómez-Ruiz S; Zizak Z; Sierra I; Prashar S; del Hierro I; Fajardo M; Juranić ZD; Kaluderović GN
Chemistry; 2009; 15(22):5588-97. PubMed ID: 19370742
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activity and mode of action of titanocene C.
Olszewski U; Claffey J; Hogan M; Tacke M; Zeillinger R; Bednarski PJ; Hamilton G
Invest New Drugs; 2011 Aug; 29(4):607-14. PubMed ID: 20162321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
